IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells

BACKGROUND: ICIs have strongly improved the outcome of NSCLC patients. However, primary and secondary resistance occur during treatment in most of the patients, with several of them developing fast progressions. Autoantibodies can be related with a dysfunctional immune system, although their associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugolini, Alessio, Zizzari, Ilaria Grazia, Ceccarelli, Fulvia, Botticelli, Andrea, Colasanti, Tania, Strigari, Lidia, Rughetti, Aurelia, Rahimi, Hassan, Conti, Fabrizio, Valesini, Guido, Marchetti, Paolo, Nuti, Marianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658668/
https://www.ncbi.nlm.nih.gov/pubmed/33166793
http://dx.doi.org/10.1016/j.ebiom.2020.103098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658668/
https://www.ncbi.nlm.nih.gov/pubmed/33166793
http://dx.doi.org/10.1016/j.ebiom.2020.103098

Ejemplares similares